NOV 27·Motley FoolLow
Biotech Fund Reveals $15 Million MoonLake Exit After Stock's 90% Crash
A brutal 90% single-day crash and a shareholder's full exit raise the stakes for MoonLake's upcoming FDA meeting.
StockHealthcare · Biotechnology
$MLTX
MoonLake Immunotherapeutics
Price · $MLTXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MLTX in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $MLTX in the last 30 days.
Top stories · $MLTXMore →
NOV 26·Benzinga
MLTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - MLTX - MoonLake ( NASDAQ:MLTX )
NEW YORK, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics ( NASDAQ:MLTX ) between March 10, 2024 and September 29, 2025, both dates inclusive ( the "Class Period" ) , of the important ...
NOV 25·Benzinga
INVESTOR REMINDER: Important MoonLake Immunotherapeutics Securities Class Action Deadline Approaching on December 15 for Investors with Losses - Contact BFA Law - MoonLake ( NASDAQ:MLTX )
NEW YORK, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics ( NASDAQ:MLTX ) and certain of the Company's senior executives for potential violations of the federal securities laws.